Bristol Myers Squibb Co (BMY): Revenue
$48.19B
Year ended 2025-12-31
$49.19B
Trailing 12 months to 2026-06-30
+1.4%
3-year compound annual growth
+2.5%
5-year compound annual growth
+11.3%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.19B | -0.2% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $48.30B | +7.3% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $45.01B | -2.5% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $46.16B | -0.5% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $46.38B | +9.1% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $42.52B | +62.6% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $26.14B | +15.9% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $22.56B | +8.6% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $20.78B | +6.9% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $19.43B | +17.3% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $16.56B | +4.3% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $15.88B | -3.1% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $16.39B | -7.0% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $17.62B | -17.1% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $21.24B | +9.0% | 2014-02-14, From 2011-01-01 |
| 2010-12-31 | $19.48B | +3.6% | 2013-02-15, From 2010-01-01 |
| 2009-12-31 | $18.81B | +6.2% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $17.71B | +13.4% | 2011-02-18, From 2008-01-01 |
| 2007-12-31 | $15.62B | n/a | 2010-02-19, From 2007-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $61.16B | +8.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗